60 Degrees Pharmaceuticals, Inc. (SXTP)
Pre-market:
- GlobeNewswire
60 Degrees Pharmaceuticals Receives FDA Orphan Drug Designation for Tafenoquine for Treatment of Patients with Acute Babesiosis
With the tafenoquine for acute babesiosis orphan drug designation, 60 Degrees Pharmaceuticals now qualifies for certain incentives, including market exclusivity, tax credits, and exemption from certain FDA filing fees.60 Degrees Pharmaceuticals recently announced it has entered into an agreement with Tufts Medical Center in Boston to conduct the world’s first clinical trial evaluating the efficacy and safety of tafenoquine in treating human babesiosis patients.FDA orphan drug designation is gran
- GlobeNewswire
Enrollment in 60 Degrees Pharmaceuticals Clinical Trial of Tafenoquine for Babesiosis to Begin at Tufts Medical Center; First Study of Its Kind
60 Degrees Pharmaceuticals has entered an agreement with Tufts Medical Center to conduct a clinical trial that will evaluate the safety and efficacy of tafenoquine for the treatment of babesiosis in humansThe study will be the world’s first clinical trial to evaluate tafenoquine in human babesiosis patientsEnrollment will begin after a site initiation visit in Boston on June 13, 2024Agreements are being negotiated with two other prominent university hospitals to expand recruitment in the Northea
- GlobeNewswire
60 Degrees Pharmaceuticals Funds Babesia spp Testing in Chronic Fatigue Patient Samples in NC State College of Veterinary Medicine Study
Long-term chronic fatigue syndrome (CFS) symptoms can be triggered by certain prior acute infectionsProminent researchers/clinicians in the tick-borne disease scientific community postulate that latent Babesia spp infections may trigger CFS symptomsPlanned study at North Carolina State College of Veterinary Medicine will assess whether Babesia spp parasites are present in samples from patients with chronic fatigue/neurologic symptoms by PCRCDC estimates CFS affects 3.3 million Americans WASHINGT
